Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas

被引:53
|
作者
Li, Haiyan [1 ]
Wang, Qun [1 ]
Gao, Fei [1 ]
Zhu, Faliang [1 ]
Wang, Xiaoyan [1 ]
Zhou, Chengjun [2 ]
Liu, Chunmei [1 ]
Chen, Yingyu [3 ]
Ma, Chunhong [1 ]
Sun, Wensheng [1 ]
Zhang, Lining [1 ]
机构
[1] Shandong Univ, Sch Med, Inst Immunol, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Hosp 2, Dept Pathol, Jinan 250021, Shandong, Peoples R China
[3] Peking Univ, Ctr Human Dis Genom, Beijing 100083, Peoples R China
关键词
programmed cell death 5; glioma; gene expression;
D O I
10.3892/or_00000044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed cell death 5 (PDCD5) is a novel apoptosis-promoting protein. Recently, a decreased expression of PDCD5 has been found in several types of human tumors. However, the expression level of PDCD5 in human gliomas has not been investigated. In the present study, we examined the expression of PDCD5 in 88 human glioma samples at both mRNA and protein levels by RT-PCR, Western blotting and immunohistochemistry. We found that 53.3% (16/30) of the glioma samples had a reduced expression of PDCD5 mRNA and 70.5% (62/88) had a reduced expression of the PDCD5 protein as compared to normal brain tissue. Furthermore, we studied the correlation of the expression level of PDCD5 with the clinicopathological grade and survival of patients with astrocytomas. Although longitudinal studies of a cohort of patients with astrocytoma revealed that PDCD5 expression was not able to predict clinical outcome (p > 0.05), a decreased expression of PDCD5 correlated significantly with high-grade astrocytomas (p < 0.001). In conclusion, our data suggest that reduced PDCD5 expression may contribute to the pathogenesis of human gliomas.
引用
收藏
页码:573 / 579
页数:7
相关论文
共 50 条
  • [31] Treatment advances in high-grade gliomas
    Chen, Xi
    Cui, Yi
    Zou, Liqun
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] Advanced treatment in high-grade gliomas
    Xiong, Lai
    Wang, Feng
    Xie, Xiao Qi
    JOURNAL OF BUON, 2019, 24 (02): : 424 - 430
  • [33] Temozolomide for Pediatric High-Grade Gliomas
    Roger J. Packer
    Current Neurology and Neuroscience Reports, 2012, 12 (2) : 111 - 113
  • [34] High-grade gliomas: reality and hopes
    Mirimanoff, Rene-Olivier
    CHINESE JOURNAL OF CANCER, 2014, 33 (01) : 1 - 3
  • [35] New approaches for high-grade gliomas
    Wolff, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 13 - 14
  • [36] Newly Diagnosed High-Grade Gliomas
    Giglio, Pierre
    Villano, John Lee
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2010, 12 (04) : 309 - 320
  • [37] MUTATION CHARACTERISTICS IN HIGH-GRADE GLIOMAS
    Kotoula, Vassiliki
    Razis, Evangelia
    Giannoulatou, Eleni
    Vrettou, Eleni
    Charalambous, Elpida
    Kouvatseas, George
    Tikas, Ioannis
    Papadopoulos, Sotiris
    Papaemmanoyil, Styliani
    Rigakos, George
    Zaramboukas, Thomas
    Romanidou, Ourania
    Iliadis, Georgios
    Nomikos, Panagiotis
    Selviaridis, Panagiotis
    Polyzoidis, Konstantinos
    Fountzilas, George
    NEURO-ONCOLOGY, 2016, 18 : 112 - 113
  • [38] Newly Diagnosed High-Grade Gliomas
    Pierre Giglio
    John Lee Villano
    Current Treatment Options in Neurology, 2010, 12 : 309 - 320
  • [39] Treatment of high-grade gliomas in the elderly
    Brandes, A
    Fiorentino, MV
    ONCOLOGY, 1998, 55 (01) : 1 - 6
  • [40] Adult high-grade malignant gliomas
    Zustovich, Fable
    Lombardi, Giuseppe
    Amirouchene, Nabil
    Pastorelli, Davide
    ONCOLOGY REVIEWS, 2008, 2 (04) : 195 - 198